Login
$XBIO
$1.49 -$0.17 (10.24%) Close

$XBIO SEC Filings

Filed On Filing
13 Nov 2026 DEFA14A
13 Nov 2026 8-K: Results of Operations and Financial Condition

Proposed share exchange transaction expected to create a multi-indication clinical stage company focused on targeting neutrophil extracellular traps (NETs)

12 Nov 2026 FORM 10-Q FOR SEP 2026
12 Nov 2026 SCHEDULE 13G/A
23 Sep 2026 8-K: Regulation FD Disclosure

Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026

18 Sep 2026 SCHEDULE 13G
16 Sep 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

______________________________________________________________________________

07 Aug 2026 8-K: Results of Operations and Financial Condition

Expanded collaborative research initiatives reinforce the Company's long-term

06 Aug 2026 FORM 10-Q FOR JUN 2026
29 May 2026 SCHEDULE 13G
14 May 2026 SCHEDULE 13G/A
13 May 2026 8-K: Results of Operations and Financial Condition

Advancements across investigator-initiated studies, translational research and

12 May 2026 QUARTERLY REPORT FOR MARCH 2026
24 Apr 2026 FORM 10-K FOR DEC 2025 AMENDMENT 1
24 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

Xenetic Biosciences, Inc. (the “Company”) hereby grants the following shares of restricted stock (“Restricted Stock”) pursuant to its Amended and Restated Equity Incentive Plan (as may be amended, the “Plan”). The terms of the grant are ...

23 Apr 2026 Form 4: Parslow James F, Interim CEO and CFO

Received 100,000 shares as a grant or award

13 Mar 2026 8-K: Results of Operations and Financial Condition

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers

12 Mar 2026 FORM 10-K FOR DEC 2025
12 Feb 2026 SCHEDULE 13G
09 Jan 2026 8-K: Other Events

On December 11, 2025, Xenetic Biosciences, Inc. (the “Company”) announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), originally scheduled for December 11, 2025, had been adjourned until January 8, 2026 in order ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support